Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Immunosuppressive properties of mesenchymal stem cells.

Abumaree M., Al Jumah M., Pace RA., Kalionis B.

Clinical Trial on Immune Modulation, published in Stem Cell Rev Rep (2012) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Rev Rep (2012)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
21892603
DOI
10.1007/s12015-011-9312-0

Abstract (original English)

Mesenchymal stem cells (MSC) can be isolated from different adult tissues including bone marrow, adipose tissue, cord blood and placenta. MSCs modulate the immune function of the major immune cell populations involved in alloantigen recognition and elimination, including antigen presenting cells, T cells, B cells and natural killer cells. Many clinical trials are currently underway that employ MSCs to treat human immunological diseases. However, the molecular mechanism that mediates the immunosuppressive effect of MSCs is still unclear and the safety of using MSC in patient needs further confirmation. Here, we review the cytokines that activate MSCs and the soluble factors produced by MSCs, which allow them to exert their immunosuppressive effects. We review the mechanism responsible, at least in part, for the immune suppressive effects of MSCs and highlight areas of research required for a better understanding of MSC immune modulation.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsClinical Trials as TopicHumansImmune System DiseasesImmune ToleranceMesenchymal Stem Cell TransplantationMesenchymal Stem CellsTranslational Research, Biomedical

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research